Management of the patient with medically refractory epilepsy

References

• Picot MC, Baldy-Moulinier M, Daures JP, Dujols P, Crespel A. The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country. Epilepsia49(7), 1230–1238 (2008).
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure9(7), 464–468 (2000).
   PubMed Web of Science ®Google Scholar
• Arts WF, Brouwer OF, Peters AC et al. Course and prognosis of childhood epilepsy: 5-year follow-up of the Dutch study of epilepsy in childhood. Brain127, 1774–1784 (2004).
   PubMed Web of Science ®Google Scholar
• Sillanpaa M, Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain129, 617–624 (2006).
   PubMed Web of Science ®Google Scholar
• Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann. Neurol.62(4), 382–389 (2007).
   PubMed Web of Science ®Google Scholar
• Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann. Neurol.62(4), 375–381 (2007).
   PubMed Web of Science ®Google Scholar
• Tetto A, Manzoni P, Millul A et al. The costs of epilepsy in Italy – a prospective cost-of-illness study in referral patients with disease of different severity. Epilepsy Res.48(3), 207–216 (2002).
   PubMed Web of Science ®Google Scholar
• Langfitt JT, Holloway RG, McDermott MP et al. Health care costs decline after successful epilepsy surgery. Neurology68(16), 1290–1298 (2007).
   PubMedGoogle Scholar
• Forsgren I, Beghi E, Ekman M. Cost of epilepsy in Europe. Eur. J. Neurol.12, 54–58 (2005).
   PubMedGoogle Scholar
• Tellez-Zenteno JF, Dhar R, Wiebe S. Long-term seizure outcomes following epilepsy surgery: a systematic review and meta-analysis. Brain128, 1188–1198 (2005).
   PubMed Web of Science ®Google Scholar
• Engel J, Wiebe S, French J et al. Practice parameter: temporal lobe and localized neocortical resections for epilepsy – report of the quality standards subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology60(4), 538–547 (2003).
   PubMed Web of Science ®Google Scholar
• Wiebe S, Blume WT, Girvin JP, Eliasziw M. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N. Engl. J. Med.345(5), 311–318 (2001).
   PubMed Web of Science ®Google Scholar
• Wieser HG, Hane A. Antiepileptic drug treatment before and after selective amygdalohippocampectomy. Epilepsy Res.55(3), 211–223 (2003).
   PubMed Web of Science ®Google Scholar
• Schmidt D, Baumgartner T, Loscher L. Seizure recurrence after planned discontinuation of antiepileptic drugs in seizure-free patients after epilepsy surgery: A review of current clinical experience. Epilepsia45(2), 179–186 (2004).
   PubMed Web of Science ®Google Scholar
• Schmidt D. Can epilepsy surgery cure epilepsy? Epilepsia45, 25–26 (2004).
   Google Scholar
• Schmidt D. Long-term seizure control of AEDs after epilepsy surgery. Ann. Neurol.56, S24–S24 (2004).
   Google Scholar
• Marchi N, Hallene KL, Kight KM et al. Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. BMC Med.2, 37 (2004).
   PubMedGoogle Scholar
• van Vliet E, Aronica E, Redeker S et al. Selective and persistent upregulation of mdr1b mRNA and P-glycoprotein in the parahippocampal cortex of chronic epileptic rats. Epilepsy Res.60(2–3), 203–213 (2004).
   PubMed Web of Science ®Google Scholar
• Rizzi M, Caccia S, Guiso G et al. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J. Neurosci.22(14), 5833–5839 (2002).
   PubMed Web of Science ®Google Scholar
• Janigro D, Perju C, Fazio V et al. Alternating current electrical stimulation enhanced chemotherapy: a novel strategy to bypass multidrug resistance in tumor cells. BMC Cancer6, 72 (2006).
   PubMed Web of Science ®Google Scholar
• DeGiorgio CM, Murray D, Markovic D, Whitehurst T. Trigeminal Nerve Stimulation for epilepsy: long-term feasibility and efficacy. Neurology72(10), 936–938 (2009).
   PubMedGoogle Scholar
• DeGiorgio CM, Shewmon A, Murray D, Whitehurst T. Pilot study of trigeminal nerve stimulation (TNS) for epilepsy: a proof-of-concept trial. Epilepsia47(7), 1213–1215 (2006).
   PubMedGoogle Scholar
• Lega BC, Halpern CH, Jaggi JL, Baltuch GH. Deep brain stimulation in the treatment of refractory epilepsy: update on current data and future directions. Neurobiol. Dis. (2009).
   PubMedGoogle Scholar
• Salanova V, Worth R. Neurostimulators in epilepsy. Curr. Neurol. Neurosci. Rep.7(4), 315–319 (2007).
   PubMed Web of Science ®Google Scholar
• Alexopoulos AV, Gonugunta V, Yang J, Boulis NM. Electrical stimulation and gene-based neuromodulation for control of medically-refractory epilepsy. Acta Neurochir. Suppl.97(Pt 2), 293–309 (2007).
   PubMedGoogle Scholar
• Klitgaard H, Matagne A, Gobert J, Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol353(2–3), 191–206 (1998).
   PubMed Web of Science ®Google Scholar
• Kaminski RM, Matagne A, Leclercq K et al. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology54(4), 715–720 (2008).
   PubMed Web of Science ®Google Scholar
• Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome. Neurology70(21), 1950–1958 (2008).
   PubMed Web of Science ®Google Scholar
• Hakimian S, Cheng-Hakimian A, Anderson GD, Miller JW. Rufinamide: a new anti-epileptic medication. Expert Opin. Pharmacother.8(12), 1931–1940 (2007).
   PubMed Web of Science ®Google Scholar
• Beydoun A, D’Souza J, Hebert D, Doty P. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev.Neurother.9(1), 33–42 (2009).
   PubMed Web of Science ®Google Scholar
• Rostock A, Tober C, Rundfeldt C et al. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res.23(3), 211–223 (1996).
   PubMed Web of Science ®Google Scholar
• Reddy DS, Rogawski MA. Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. J. Pharmacol. Exp. Ther.295(3), 1241–1248 (2000).
   PubMed Web of Science ®Google Scholar
• Kerrigan JF, Shields WD, Nelson TY et al. Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial. Epilepsy Res.42(2–3), 133–139 (2000).
   PubMed Web of Science ®Google Scholar
• Levy R, Cooper P. Ketogenic diet for epilepsy. Cochrane Database Syst. Rev.3, CD001903 (2003).
   Google Scholar
• Vining EP, Freeman JM, Ballaban-Gil K et al. A multicenter study of the efficacy of the ketogenic diet. Arch. Neurol.55(11), 1433–1437 (1998).
   PubMedGoogle Scholar
• Keene DL. A systematic review of the use of the ketogenic diet in childhood epilepsy. Pediatr. Neurol.35(1), 1–5 (2006).
   PubMed Web of Science ®Google Scholar
• Henderson CB, Filloux FM, Alder SC, Lyon JL, Caplin DA. Efficacy of the ketogenic diet as a treatment option for epilepsy: meta-analysis. J. Child Neurol.21(3), 193–198 (2006).
   PubMed Web of Science ®Google Scholar
• Groesbeck DK, Bluml RM, Kossoff EH. Long-term use of the ketogenic diet: outcomes of 28 children with over 6 years diet duration. Neurology66(5), A41–A41 (2006).
   PubMedGoogle Scholar
• Groesbeck DK, Bluml RM, Kossoff EH. Long-term use of the ketogenic diet in the treatment of epilepsy. Dev. Med. Child Neurol.48(12), 978–981 (2006).
   PubMed Web of Science ®Google Scholar
• Bough KJ, Rho JM. Anticonvulsant mechanisms of the ketogenic diet. Epilepsia48(1), 43–58 (2007).
   PubMed Web of Science ®Google Scholar
• Schachter SC. Botanicals and herbs: a traditional approach to treating epilepsy. Neurotherapeutics6(2), 415–420 (2009).
   PubMedGoogle Scholar
• Gayatri NA, Ferrie CD, Cross H. Corticosteroids including ACTH for childhood epilepsy other than epileptic spasms. Cochrane Database Syst. Rev.1, CD005222 (2007).
   Google Scholar
• Nolan M, Bergazar M, Chu B, Cortez MA, Snead OC 3rd. Clinical and neurophysiologic spectrum associated with atypical absence seizures in children with intractable epilepsy. J. Child Neurol.20(5), 404–410 (2005).
   PubMedGoogle Scholar
• Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia46(11), 1724–1743 (2005).
   PubMed Web of Science ®Google Scholar
• Verhelst H, Boon P, Buyse G et al. Steroids in intractable childhood epilepsy: clinical experience and review of the literature. Seizure14(6), 412–421 (2005).
   PubMed Web of Science ®Google Scholar
• Gupta R, Appleton R. Corticosteroids in the management of the paediatric epilepsies. Arch. Dis.Child.90(4), 379–384 (2005).
   PubMedGoogle Scholar
• Araki T, Otsubo H, Makino Y et al. Efficacy of dexamathasone on cerebral swelling and seizures during subdural grid EEG recording in children. Epilepsia47(1), 176–180 (2006).
   PubMedGoogle Scholar
• Cucullo L, Hallene K, Dini G, Dal Toso R, Janigro D. Glycerophosphoinositol and dexamethasone improve transendothelial electrical resistance in an in vitro study of the blood–brain barrier. Brain Res.997(2), 147–151 (2004).
   PubMed Web of Science ®Google Scholar
• van Vliet EA, da Costa-Araujo S, Redeker S, van Schaik R, Aronica E, Gorter JA. Blood–brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain130(Pt 2), 521–534 (2007).
   PubMed Web of Science ®Google Scholar
• Seiffert E, Dreier JP, Ivens S et al. Lasting blood–brain barrier disruption induces epileptic focus in the rat somatosensory cortex. J. Neurosci.24(36), 7829–7836 (2004).
   PubMed Web of Science ®Google Scholar
• Tomkins O, Kaufer D, Korn A et al. Frequent blood–brain barrier disruption in the human cerebral cortex. Cell. Mol. Neurobiol.21(6), 675–691 (2001).
   PubMed Web of Science ®Google Scholar
• Marchi N, Angelov L, Masaryk T et al. Seizure-promoting effect of blood–brain barrier disruption. Epilepsia48(4), 732–742 (2007).
   PubMed Web of Science ®Google Scholar
• Marchi N, Oby E, Fernandez N et al.In vivo and in vitro effects of pilocarpine: relevance to epileptogenesis. Epilepsia48(10), 1934–1946 (2007).
   PubMed Web of Science ®Google Scholar
• Fabene PF, Navarro MG, Martinello M et al. A role for leukocyte–endothelial adhesion mechanisms in epilepsy. Nat. Med.14(12), 1377–1383 (2008).
   PubMed Web of Science ®Google Scholar
• Vezzani A, Janigro D. Inflammation. In: Epilepsy: a Comprehensive Textbook. Engel G, Pedley TA (Eds). Lippincott, Williams and Wilkins, PA, USA 267–276 (2008).
   Google Scholar
• Marchi N, Batra A, Fan Q et al. Antagonism of peripheral inflammation prevents status epilepticus. Neurobiol. Dis.33(2), 171–271 (2009).
   PubMed Web of Science ®Google Scholar
• Cavalheiro EA, Naffah-Mazzacoratti MG, Mello LE, Leite JP. The pilocarpine model of seizures. In: Models of Seizures and Epilepsy. Pitkanen A, Mosh’e SL, Schwartzkroin PA (Eds). Elsevier, NY, USA 443–446 (2006).
   Google Scholar
• Marchi N, Betto G, Fazio V et al. Blood–brain barrier damage and brain penetration of antiepileptic drugs: role of serum proteins and brain edema. Epilepsia50(4), 664–677 (2009).
   PubMedGoogle Scholar
• Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci.6(8), 591–602 (2005).
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA97(7), 3473–3478 (2000).
   PubMed Web of Science ®Google Scholar
• Siddiqui A, Kerb R, Weale ME et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med.348(15), 1442–1448 (2003).
   PubMed Web of Science ®Google Scholar
• Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y. Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. Epilepsia50(4), 898–903 (2008).
   PubMedGoogle Scholar
• Oby E, Janigro D. The blood–brain barrier and epilepsy. Epilepsia47(11), 1761–1774 (2006).
   PubMed Web of Science ®Google Scholar
• Loscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J. Pharmacol. Exp. Ther.301(1), 7–14 (2002).
   PubMed Web of Science ®Google Scholar
• Perucca E. Current trends in antiepileptic drug therapy. Epilepsia44(Suppl. 4), 41–47 (2003).
   PubMedGoogle Scholar
• Perucca E. An introduction to antiepileptic drugs. Epilepsia46(Suppl. 4), 31–37 (2005).
   PubMed Web of Science ®Google Scholar
• Sisodiya SM. Malformations of cortical development: burdens and insights from important causes of human epilepsy. Lancet Neurol.3(1), 29–38 (2004).
   PubMed Web of Science ®Google Scholar
• Vreugdenhil M, Wadman WJ. Modulation of sodium currents in rat CA1 neurons by carbamazepine and valproate after kindling epileptogenesis. Epilepsia40(11), 1512–1522 (1999).
   PubMedGoogle Scholar
• Remy S, Urban BW, Elger CE, Beck H. Anticonvulsant pharmacology of voltage-gated Na+ channels in hippocampal neurons of control and chronically epileptic rats. Eur. J. Neurosci.17(12), 2648–2658 (2003).
   PubMed Web of Science ®Google Scholar
• Remy S, Gabriel S, Urban BW et al. A novel mechanism underlying drug resistance in chronic epilepsy. Ann. Neurol.53(4), 469–479 (2003).
   PubMed Web of Science ®Google Scholar
• Ragozzino D, Palma E, Di Angelantonio S et al. Rundown of GABA type A receptors is a dysfunction associated with human drug-resistant mesial temporal lobe epilepsy. Proc. Natl Acad. Sci. USA102(42), 15219–15223 (2005).
   PubMedGoogle Scholar
• Oby E, Caccia S, Vezzani A et al.In vitro responsiveness of human-drug-resistant tissue to antiepileptic drugs: insights into the mechanisms of pharmacoresistance. Brain Res.1086(1), 201–213 (2006).
   PubMed Web of Science ®Google Scholar
• Loscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia50(1), 1–23 (2009).
   PubMed Web of Science ®Google Scholar
• Schmidt D, Loscher W. New developments in antiepileptic drug resistance: an integrative view. Epilepsy Curr.9(2), 47–52 (2009).
   PubMed Web of Science ®Google Scholar
• Dombrowski S, Desai S, Marroni M et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia42(12), 1504–1507 (2001).
   Google Scholar
• Aronica E, Gorter JA, Ramkema M et al. Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia45(5), 441–451 (2004).
   PubMed Web of Science ®Google Scholar
• Aronica E, Gorter JA, Redeker S et al. Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia46(6), 849–857 (2005).
   PubMed Web of Science ®Google Scholar
• Sisodiya SM, Beck H, Loescher W, Vezzani A. Mechanisms of Drug Resistance. In: Epilepsy: a Comprehensive Textbook. Engel G, Pedley TA (Eds.). Lippincott Williams and Wilkins, PA, USA 1279–1290 (2008).
   Google Scholar
• Marchi N, Guiso G, Caccia S et al. Determinants of drug brain uptake in a rat model of seizure-associated malformations of cortical development. Neurobiol. Dis.24(3), 429–442 (2006).
   PubMed Web of Science ®Google Scholar
• Pusztai L, Wagner P, Ibrahim N et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer104(4), 682–691 (2005).
   PubMed Web of Science ®Google Scholar
• Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics2(1), 51–64 (2001).
   PubMed Web of Science ®Google Scholar
• Granata T, Obino L, Ragona F et al. Steroid treatment is effective in the treatement of status epilepticus in children. Program and Abstracts of the 62nd Annual Meeting of the American Epilepsy Society. Seattle, WA, USA, 5–9 December 2008 (Abstract 8853).
   Google Scholar
• Takano A, Kusuhara H, Suhara T et al. Evaluation of in vivo P-glycoprotein function at the blood–brain barrier among MDR1 gene polymorphisms by using C-11-verapamil. J. Nucl. Med.47(9), 1427–1433 (2006).
   PubMed Web of Science ®Google Scholar